EUZG Stock Overview

Manufactures and sells isotope technology components worldwide. More details

EUZG fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	3/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 24.3% below our estimate of its fair value

Earnings are forecast to grow 14.29% per year

Earnings grew by 10.1% over the past year

Risk Analysis

Shares are highly illiquid

Eckert & Ziegler SE Competitors

Nakanishi

TSE:7716

JP¥187.6b

Angelalign Technology

SEHK:6699

HK$9.9b

LifeTech Scientific

SEHK:1302

HK$7.0b

Shanghai MicroPort EP MedTech

SHSE:688351

CN¥9.1b

Price History & Performance

Summary of share price highs, lows and changes for Eckert & Ziegler
Historical stock prices
Current Share Price	€55.90
52 Week High	€57.45
52 Week Low	€55.25
Beta	1.36
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-2.10%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	EUZG	AT Medical Equipment	AT Market
7D	-2.1%	0.6%	-0.9%
1Y	n/a	4.6%	16.1%

Return vs Industry: Insufficient data to determine how EUZG performed against the Austrian Medical Equipment industry.

Return vs Market: Insufficient data to determine how EUZG performed against the Austrian Market.

Price Volatility

Is EUZG's price volatile compared to industry and market?
EUZG volatility
EUZG Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	6.2%
Market Average Movement	4.3%
10% most volatile stocks in AT Market	8.3%
10% least volatile stocks in AT Market	2.5%

Stable Share Price: EUZG's share price has been volatile over the past 3 months compared to the Austrian market.

Volatility Over Time: Insufficient data to determine EUZG's volatility change over the past year.

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

About the Company

Founded	Employees	CEO	Website
2024	1,143	Harald Hasselmann	www.ezag.com

Eckert & Ziegler SE manufactures and sells isotope technology components worldwide. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of uveal melanomas; brain seed, HDR and brachytherapy; ophthalmological products; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceuticals, laboratory equipment, radiosynthesis equipment, quality-control equipment, consumables, therapeutic products and plant engineering, and other services.

Eckert & Ziegler SE Fundamentals Summary

How do Eckert & Ziegler's earnings and revenue compare to its market cap?
EUZG fundamental statistics
Market cap	€1.17b
Earnings (TTM)	€35.90m
Revenue (TTM)	€277.72m

32.5x

P/E Ratio

4.2x

P/S Ratio

Is EUZG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EUZG income statement (TTM)
Revenue	€277.72m
Cost of Revenue	€144.30m
Gross Profit	€133.43m
Other Expenses	€97.52m
Earnings	€35.90m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Mar 27, 2025

Earnings per share (EPS)	1.72
Gross Margin	48.04%
Net Profit Margin	12.93%
Debt/Equity Ratio	8.6%

How did EUZG perform over the long term?

See historical performance and comparison

Dividends

0.09%

Current Dividend Yield

3%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/26 03:42
End of Day Share Price	2025/03/25 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Eckert & Ziegler SE is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Adrian Kowollik	Dr. Kalliwoda Research
Alexander Galitsa	Hauck Aufhäuser Investment Banking
Simon Keller	Hauck Aufhäuser Investment Banking